Cat. No. 0443
Chemical Name: N-[2-(6-Chloro-5-methoxyindol-3-yl)
Biological ActivityPotent melatonin agonist (pKi values are 9.10 and 9.77 for human recombinant MT1 and MT2 receptors respectively). Displays higher affinity for binding to hamster brain membrane and chicken retina than melatonin.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
on-line. Please contact Customer Service
Browning et al (2000) Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors. Br.J.Pharmacol. 129 877. PMID: 10696085.
Dubocovich (1995) Melatonin receptors: are there multiple subtypes? TiPS 16 50. PMID: 7762083.
Dubocovich (1988) Luzindole (NO 774): A novel melatonin receptor antagonist. J.Pharmacol.Exp.Ther. 246 902. PMID: 2843633.
Duncan et al (1988) 2-[125I]Iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution. Endocrinology 122 1825. PMID: 2834175.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses 6-Chloromelatonin from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: 6-Chloromelatonin, supplier, Melatonin, agonists, MT, Receptors, Tocris Bioscience, Melatonin Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally availableA 971432
Potent and selective S1P5 agonistGLPG 0974
Potent FFA2 antagonistOgerin
Selective positive allosteric modulator at GPR68BGC 20-1531 hydrochloride
High affinity and selective EP4 antagonistMontelukast sodium
CysLT1 and GPR17 antagonist
October 30 - November 3, 2016
Boston, MA, USA